Markets · 1 sources covering this

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

Aurobindo Pharma said the US FDA conducted a routine inspection of its wholly owned step-down subsidiary in the US from 17th to 21st August 2026, which concluded with four observations.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

MintLean R·1h ago
Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA
Aurobindo Pharma said the US FDA conducted a routine inspection of its wholly owned step-down subsidiary in the US from 17th to 21st August 2026, which concluded with four observations.
Read at Mint →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/36229f9fa886f7ec335a1f60ce544df0a61ae187"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA"></iframe>

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

How 1 sources are covering this

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

More from Markets

Markets brace for more hawkish ECB as energy risks threaten to keep inflation elevated

Augmont Enterprises IPO day 2: Issue subscribed over 9 times; GMP signals nearly 50% listing pop; apply or not?

Global Market: China’s property crisis deepens as Evergrande founder gets life sentence

Infosys, HCLTech, other IT stocks gain on Nvidia’s likely price hikes. Are AI bubble worries coming true?

Reader

Trust & legal

Across the network